These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16465840)

  • 1. [Thrombolysis-treated ST-segment elevation myocardial infarction. Clopidogrel administration should be a standard].
    Eriksson P
    Lakartidningen; 2006 Jan 11-17; 103(1-2):21. PubMed ID: 16465840
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
    Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.
    Scirica BM; Sabatine MS; Morrow DA; Gibson CM; Murphy SA; Wiviott SD; Giugliano RP; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2006 Jul; 48(1):37-42. PubMed ID: 16814646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
    Lin GM; Han CL
    Am J Emerg Med; 2010 Mar; 28(3):382-3. PubMed ID: 20223400
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Gibson CM; Pride YB; Buros JL; Lord E; Shui A; Murphy SA; Pinto DS; Zimetbaum PJ; Sabatine MS; Cannon CP; Josephson ME;
    J Am Coll Cardiol; 2008 Feb; 51(5):546-51. PubMed ID: 18237683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clopidogrel plus aspirin on ST segments in patients with ST-elevation acute myocardial infarction.
    Jabaren M; Desai DM; Arabi A; Kareti G; Chen-Scarabelli C; Rosman HS
    Am J Cardiol; 2006 Dec; 98(11):1435-8. PubMed ID: 17126645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
    J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.
    Heestermans AA; van Werkum JW; Taubert D; Seesing TH; von Beckerath N; Hackeng CM; Schömig E; Verheugt FW; ten Berg JM
    Thromb Res; 2008; 122(6):776-81. PubMed ID: 18455217
    [No Abstract]   [Full Text] [Related]  

  • 13. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Pride YB; Appelbaum E; Lord EE; Sloan S; Cannon CP; Sabatine MS; Gibson CM;
    Am J Cardiol; 2009 Aug; 104(4):475-9. PubMed ID: 19660597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD; Braunwald E; Angiolillo DJ; Meisel S; Dalby AJ; Verheugt FW; Goodman SG; Corbalan R; Purdy DA; Murphy SA; McCabe CH; Antman EM;
    Circulation; 2008 Oct; 118(16):1626-36. PubMed ID: 18757948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
    Matetzky S; Fefer P; Shenkman B; Varon D; Savion N; Hod H
    Am J Cardiol; 2008 Sep; 102(5):524-9. PubMed ID: 18721506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.
    Sherwood MW; Morrow DA; Scirica BM; Jiang S; Bode C; Rifai N; Gerszten RE; Gibson CM; Cannon CP; Braunwald E; Sabatine MS
    Am Heart J; 2010 Jun; 159(6):964-971.e1. PubMed ID: 20569707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
    Zeymer U; Gitt AK; Zahn R; Jünger C; Bauer T; Köth O; Heer T; Wienbergen H; Gottwik M; Senges J
    Acute Card Care; 2008; 10(1):43-8. PubMed ID: 17924233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
    Fefer P; Hod H; Hammerman H; Segev A; Beinart R; Boyko V; Behar S; Matetzky S
    Am J Cardiol; 2009 Aug; 104(4):514-8. PubMed ID: 19660604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
    J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.